NCT01508858View on ClinicalTrials.gov

Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order

DRUG

placebo

Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order

DRUG

levonorgestrel / ethinylestradiol

One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period

Trial Locations (1)

75323

Novo Nordisk Investigational Site, Uppsala

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01508858 - Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women | Biotech Hunter | Biotech Hunter